Co-marketing Cooperation Project hits

2022-03-16

On December 24, 2021.Sumitomo Pharma (Suzhou) Co., Ltd.ceuticals (Suzhou) Co., Ltd. (hereinafter referred to as Sumitomo Pharma (Suzhou) Co., Ltd.ceuticals) and Shanghai Pharmaceutical Co., Ltd. (hereinafter referred to as SHAPHAR) jointly held the "Annual ALM-CSO Project Meeting" to celebrate a notable achievement resulting from the joint efforts of both teams: the "ALM-CSO" Co-marketing Project in 2021 hit the RMB 100 million yuan mark. Chairman of the Board, President and CEO Noguchi Naoki, Senior Vice President and Head of Commercial Management Dept. Kami Yasuhiro, Vice President Xue Jun and Head of Marketing Dept. Fu Nan of Sumitomo Pharma (Suzhou) Co., Ltd.ceuticals, and Executive Director, Vice President and General Manager Li Yongzhong, Deputy General Manager Tang Pengcheng, Deputy General Manager Zhang Yan, Deputy General Manager Song Lulu and Assistant General Manager Xu Keda of SHAPHAR attended this meeting.

In April 2020Sumitomo Pharma (Suzhou) Co., Ltd.ceuticals and SHAPHAR launched a co-marketing cooperation pilot project for non-targeted omni-channel full-format markets of the prescription drug "Almarl" in 13 provinces. Since January 2021, the area of the co-marketing cooperation project has expanded to the whole country.

Mr. Noguchi Naoki, Chairman of the Board, President and CEO of Sumitomo Pharma (Suzhou) Co., Ltd.ceuticals expressed his gratitude for the joint efforts of both teams over the past year in the following terms: “2021 is the second year of the "ALM-CSO" Co-marketing Project between Sumitomo Pharma (Suzhou) Co., Ltd.ceuticals and SHAPHAR. The achievement is significant and is worth celebrating. The cooperation scale has exceeded "RMB 100 million", and sales have increased by more than 30% compared with the same period last year. The project is highly valued by the DSP head office in Japan as the first co-marketing project involving Sumitomo Pharma (Suzhou) Co., Ltd.ceuticals. We expect that SHAPHAR’s team can leverage the channel’s advantages of the national supply chain network and professional teams to enhance synergy and drive the ALM-CSO Co-marketing project to greater achievements. I believe that with the joint efforts of both teams, we will continue to develop a more efficient co-marketing model, expand business into multiple directions, grow together and quickly adapt to changes in the market environment. Taking advantage of the cooperation opportunity of the project,Sumitomo Pharma (Suzhou) Co., Ltd.ceuticals will adhere to the "patient-centered" philosophy, listen carefully to the voices of patients and doctors, and help more patients suffering from cardiovascular disease as well as their families”.

Li Yongzhong, Executive Director and Vice President of Shanghai Pharma and General Manager of SHAPHAR, expressed his gratitude for the trust and support provided by Sumitomo’s team in the partnership. “SHAPHAR feels honored as the first co-marketing partner of Sumitomo Pharma (Suzhou) Co., Ltd.ceuticals in China. Through the continuous efforts of both teams, the agreed sales target will soon be achieved in 2021; in addition, we have achieved mutual learning and growth in the process of cooperation. Today, we are here to compliment front-line employees who have made outstanding contributions to the "ALM-CSO" Co-marketing Project, in order to encourage more SHAPHAR employees to devote their time and energy and play their full roles in the project,” said Li Yongzhong. “The contract sales segment has become one of the core business segments of SHAPHAR, and we have confidence in building the contract sales team of SHAPHAR as a benchmark in the industry. In the ever-changing market environment, we will continue to support and invest in contract sales, leverage the overall advantages of SHAPHAR, actively expand the terminal market, and achieve in-depth market coverage of cooperative products.”

Surpassing the “RMB 100 million” mark is an important milestone for both cooperating parties in the "ALM-CSO" Co-marketing Project. The project will continue to rely on the nationwide supply chain network of SHAPHAR and patient-centered professional education to ensure that this prescription drug is used for the diagnosis and treatment in the hospital channel while its accessibility will be improved in the out-of-hospital channel, in order to better serve the majority of patients.

[Company profiles]

·Sumitomo Pharma (Suzhou) Co., Ltd.ceuticals (Suzhou) Co., Ltd.

Sumitomo Pharma (Suzhou) Co., Ltd.ceuticals (Suzhou) Co., Ltd. has expanded in China as one of the most important market operation bases since entering the Chinese market in the 1990s. The Company has introduced international and cutting-edge production technologies into China to provide patients with high-quality products and medical solutions in multiple fields such as the central nervous system, anti-infection, cardiovascular health and the digestive tract, benefiting a large number of patients over the years. Meanwhile, Sumitomo Pharma (Suzhou) Co., Ltd.ceuticals also actively participates in various social and public welfare undertakings, and supports the in-depth development of China's health care. Sumitomo Pharma (Suzhou) Co., Ltd.ceuticals will adhere to the company values of "Based in China, continue to create and contribute new value to human health and happiness", further the philosophy of "patient-centered" to provide high-quality pharmaceuticals, and strive to make continuous contributions to the long-term development of China's medical industry.

·Shanghai Pharmaceutical Co., Ltd.

Shanghai Pharmaceutical Co., Ltd. is a modern provider of pharmaceutical supply chain services that focuses on pharmaceutical distribution. At present, it is considered one of the pharmaceutical enterprises with large scale, extensive network and strong competence in China. Based on the establishment of a national terminal network, the company strives to promote hospital supply chain services and build new industrial advantages. The company insists on deepening service innovation, building an innovative drug service platform, speeding up industrial breakthrough and devoting itself to creating a "national modern pharmaceutical supply chain service platform". With the original intention of "being proud of service" and driven by "technology + finance + service", the Company is accelerating its transformation into a world-class technology-based health service enterprise, to incite dynamism into the Chinese pharmaceutical industry.

[Statement]

1. The information in this article is for informational purposes only. Please follow the advice or guidance of your doctor or other health care professionals.

2. This article aims to convey the cutting-edge information and research progress of the medical industry, and does not constitute the commercial promotion of any medicine or the recommendation of any diagnostic or treatment scheme.

3. Please consult health care professionals for more information about diseases, medicines, diagnosis and treatment as well as other related information.

4. Please refer to product specifications for the pharmaceutical products mentioned in this article.

5. Photos and content have been authorized by the attendees. In case of any infringement, please contact us immediately, and we will handle it promptly.